Tonix Pharmaceuticals CEO Interviewed On CEOLive.TV

Tonix Pharmaceuticals Holding Corp. (OTCBB: TNXP) (“TONIX” or the “Company”), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”), including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder (“PTSD”), today announced that Chief Executive Officer Seth Lederman, MD, was interviewed by CEOLive.TV. In the interview, Dr. Lederman said that the Company has the technology and management team well-positioned to meet unmet medical needs with potential new products for FM and PTSD. The interview is available at: http://www.ceonews.tv/tnxp/.

The Company’s lead programs are potential new treatments for FM and PTSD. TONIX seeks to use new doses and formulations of cyclobenzaprine in new treatment regimens in each of these programs. Cyclobenzaprine is the active ingredient of two prescription muscle relaxants that have been approved by the U.S. Food and Drug Administration (“FDA”) and are marketed by other companies.

Dr. Lederman, a physician, scientist, and specialty pharmaceuticals entrepreneur, said that TONIX’s core technology improves the quality of sleep which can decrease pain and suffering in patients with chronic pain syndromes. Increasing the quality of sleep is an important and often overlooked problem in such patients, Dr. Lederman noted. TNX-102 is TONIX’s product candidate for FM and is being prepared for a pivotal trial early next year.

For PTSD, which impacts an estimated 25% of troops returning from Afghanistan and Iraq, TONIX’s re-formulation of cyclobenzaprine is TNX-105, Dr. Lederman said.

Dr. Lederman cited recent additions to TONIX’s management team and board that underscore the Company’s goals of advancing its clinical development programs to FDA approval and commercialization and improving communications to investors.

Leland Gershell, MD, PhD joined TONIX as Chief Financial Officer in April 2012. Dr. Gershell was most recently Managing Director and Senior Analyst at Madison Williams and Company, where he was responsible for research on specialty pharmaceutical and biotechnology companies.

If you liked this article you might like

Mirati Skyrockets On Positive Data - Biotech Movers

5 Stocks Poised for Major Breakouts

Can You Catch These 6 Stocks Under $10 on Their Way Up?

6 Stocks Under $10 Making Big Moves Higher

Trade These 5 Breakout Stocks for Big Gains